Sparrow Pharmaceuticals Presents ePoster on SPI-62 at the 25th European Congress of Endocrinology
2023-05-13
临床2期临床结果临床1期
PORTLAND, Ore.--(BUSINESS WIRE)--Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, today presented an ePoster on its lead candidate and HSD-1 inhibitorHSD-1 inhibitor SPI-62 during a session, titled “Controlling intracellular cortisol: Can HSD-1 inhibition reduce Cushing’s syndrome morbidity and minimize adrenal insufficiency risk?” at the 25th European Congress of Endocrinology (ECE 2023).
'That distinction, if realized, would provide strong clinical differentiation for SPI-62.'
“We highlight that, unlike current treatments for Cushing’s syndrome, HSD-1 inhibitorsHSD-1 inhibitors such as SPI-62 might not be expected to carry risk of adrenal crisis,” said Frank Czerwiec, M.D., Ph.D, Chief Medical Officer at Sparrow Pharmaceuticals and ePoster presenter. “That distinction, if realized, would provide strong clinical differentiation for SPI-62.”
David A. Katz, Ph.D., Chief Scientific Officer at Sparrow Pharmaceuticals added, “SPI-62 directly reduces intracellular cortisol that binds to intracellular receptors and thereby causes the serious health complications of glucocorticoid excess including weight gain, diabetes, hypertension, osteoporosis, depression, and cognitive changes. Even with complete HSD-1 inhibition, though, circulating cortisol can diffuse into cells in amounts sufficient to maintain life-critical functions such as stress response. We summarize our and others’ data that indicate how HSD-1 inhibition can reset intracellular cortisol to avoid morbidity associated with either excessive or insufficient levels.”
SPI-62 is a potent HSD-1 inhibitorHSD-1 inhibitor in clinical development for treatment of Cushing’s syndrome and autonomous cortisol secretion, and as adjunctive therapy to prednisolone in polymyalgia rheumatica. In prior Phase 1 and Phase 2 clinical trials, SPI-62 was associated with maximal liver, adipose, and brain HSD-1 inhibition at generally well tolerated doses.
To view the abstract, visit ECE’s website.
To learn more about Sparrow Pharmaceuticals SPI-62, visit www.sparrowpharma.com.
About Sparrow Pharmaceuticals
Sparrow Pharmaceuticals was founded to spare patients the ravages of steroids. Leveraging underappreciated scientific insights into glucocorticoid biology, the company is working to provide better treatment options for serious disorders of hypercortisolism, and to revolutionize the treatment of autoimmune and inflammatory conditions. Its lead product, SPI-62, is an oral, small molecule, novel therapeutic treatment designed to target the source of active intracellular glucocorticoids in key tissues.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。